Analyst Research

Report Title Price
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: ValuEngine, Inc.
$25.00
Provider: Reuters Investment Profile
$20.00
Provider: Pechala's Reports
$15.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Committee for Medicinal Products for Human Use Adopts Positive Opinion on NovoRapid PumpCart Developed in Partnership between Novo Nordisk A/S and Roche Diabetes Care


Thursday, 21 Nov 2013 07:00pm EST 

Novo Nordisk A/S announced that the Committee for Medicinal Products for Human Use (CHMP) under the European Medicines Agency (EMA) adopted positive opinion recommending marketing of NovoRapid PumpCart in Europe. NovoRapid PumpCart has been developed in a non-exclusive partnership between Roche Diabetes Care and Novo Nordisk. NovoRapidPumpCartis a 1.6 ml prefilled insulin pump cartridge containing the rapid-acting insulin NovoRapidfrom Novo Nordisk. It is compatible with Roche Diabetes Care’s Accu-Chek Insight diabetes therapy system. 

Company Quote

45.41
-0.28 -0.61%
4:01pm EDT